These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 36851314)
1. Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population. Kara A; Coskun A; Temel F; Özelci P; Topal S; Ates İ Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851314 [TBL] [Abstract][Full Text] [Related]
2. Analysis of participant-reported adverse events following the first dose of inactivated SARS-Cov-2 vaccine (TURKOVAC™) through telephone survey in Türkiye. Kara A; Coskun A; Temel F; Özelci P; Topal S; Ateş I Ann Med; 2023 Dec; 55(1):1070-1079. PubMed ID: 36908270 [TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
4. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination. Li L; Robinson LB; Patel R; Landman AB; Fu X; Shenoy ES; Hashimoto DM; Banerji A; Wickner PG; Samarakoon U; Mancini CM; Zhang Y; Blumenthal KG JAMA Netw Open; 2021 Oct; 4(10):e2131034. PubMed ID: 34698847 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. Al Kaabi N; Yang Y; Eldin Hussein S; Yang T; Abdalla J; Wang H; Lou Z; Chinese Center For Disease Control And Prevention ; Bakkour A; Arafat A; China National Biotec Group Company Limited ; Jiang Z; Tian Y; National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd ; Beijing Institute Of Biological Products Company Limited ; Xiao P; Zaher W; Eltantawy I; Wang C; Xu G; Zhang Y; Yang X Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851177 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM; Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274 [TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis is a rare reaction in COVID-19 vaccination. Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336 [TBL] [Abstract][Full Text] [Related]
9. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S; Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358 [TBL] [Abstract][Full Text] [Related]
14. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. Greenhawt M; Abrams EM; Shaker M; Chu DK; Khan D; Akin C; Alqurashi W; Arkwright P; Baldwin JL; Ben-Shoshan M; Bernstein J; Bingemann T; Blumchen K; Byrne A; Bognanni A; Campbell D; Campbell R; Chagla Z; Chan ES; Chan J; Comberiati P; Dribin TE; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Grayson MH; Horner CC; Hourihane J; Katelaris CH; Kim H; Kelso JM; Lang D; Ledford D; Levin M; Lieberman J; Loh R; Mack D; Mazer B; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Oppenheimer J; Perrett KP; Ramsey A; Rank M; Robertson K; Sheikh J; Spergel JM; Stukus D; Tang MLK; Tracy JM; Turner PJ; Whalen-Browne A; Wallace D; Wang J; Waserman S; Witry JK; Worm M; Vander Leek TK; Golden DBK J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3546-3567. PubMed ID: 34153517 [TBL] [Abstract][Full Text] [Related]
15. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Allergic Reactions following COVID - 19 Vaccination in Patients with Documented Allergies. Shukla SC; Pandit S; Soni D; Gogtay NJ J Assoc Physicians India; 2021 Oct; 69(10):11-12. PubMed ID: 34781647 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z; EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435 [TBL] [Abstract][Full Text] [Related]
18. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771 [TBL] [Abstract][Full Text] [Related]
19. Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy). Filon FL; Lazzarato I; Patriarca E; Iavernig T; Peratoner A; Perri G; Ponis G; Rocco G; Cegolon L Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298481 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]